Loading...
News 2018-04-27T13:47:37+00:00

News

Number Title Author Date
25
Alteogen Inc. Becomes First Mover for Eylea Biosimilar with securing global competitiveness by registering patent
alteogen | 2019.01.04 | Votes 0 | Views 93
alteogen 2019.01.04
24
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
alteogen | 2018.12.04 | Votes 0 | Views 94
alteogen 2018.12.04
23
Alteogen's Kadcyla biobetter gains edge in gastric cancer with FDA orphan designation
alteogen | 2018.08.17 | Votes 0 | Views 103
alteogen 2018.08.17
22
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
alteogen | 2018.08.07 | Votes 0 | Views 97
alteogen 2018.08.07
21
Alteogen develops antibody transferring IV to SC injection
alteogen | 2018.07.30 | Votes 0 | Views 107
alteogen 2018.07.30
20
Alteogen, Lynkogen targeting large NASH, diabetes markets in cross-royalty collaboration
alteogen | 2018.07.11 | Votes 0 | Views 94
alteogen 2018.07.11
19
Alteogen and Lynkogen Enter into an Exclusive Option Agreement
alteogen | 2018.07.04 | Votes 0 | Views 97
alteogen 2018.07.04
18
18 January 2018 Bio & Medicine Alteogen to seek US approval for clinical trials of Eylea biosimilar
alteogen | 2018.05.28 | Votes 0 | Views 130
alteogen 2018.05.28
17
23 Aug. 2017 Alteogen set to start phase I trial of ADC product in Korea
alteogen | 2018.05.28 | Votes 0 | Views 61
alteogen 2018.05.28
16
26 APR 2017 Alteogen partners with Cristalia to develop long-acting growth hormone
alteogen | 2018.05.28 | Votes 0 | Views 73
alteogen 2018.05.28